Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Farmaceutica RemediaLTS:0M8I 58 Return-on-Tangible-Asset is 0.73% as of Mar. 2026, which is 66% below its 10-year median of 2.13. GuruFocus rates LTS:0M8I with a GF Score™ of 58/100 and a GF Value™ of lei0.23. The stock has 8 warning signs investors should review. Among 120 Medical Distribution companies, Farmaceutica Remedia ranks worse than 61.67% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Farmaceutica Remedia's annualizedNet Income for the quarter that ended in Mar. 2026 was lei2.7 Mil. Farmaceutica Remedia's average total tangible assets for the quarter that ended in Mar. 2026 was lei367.4 Mil. Therefore, Farmaceutica Remedia's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2026 was 0.73%.
The historical rank and industry rank for Farmaceutica Remedia's Return-on-Tangible-Asset or its related term are showing as below:
LTS:0M8I'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: 0.87 Med: 2.13 Max: 15.13
Current: 1.62
During the past 13 years, Farmaceutica Remedia's highest Return-on-Tangible-Asset was 15.13%. The lowest was 0.87%. And the median was 2.13%.
LTS:0M8I's Return-on-Tangible-Asset is ranked worse than 61.67% of 120
companies
in the Medical Distribution industry
Industry Median: 2.43
vs LTS:0M8I: 1.62
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Farmaceutica Remedia Return-on-Tangible-Asset Related Terms
Farmaceutica Remedia Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Farmaceutica Remedia's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0M8I vs MCK, COR, CAH: Return-on-Tangible-Asset Comparison
For the Medical Distribution subindustry, Farmaceutica Remedia's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Farmaceutica Remedia Return-on-Tangible-Asset vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Farmaceutica Remedia's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Farmaceutica Remedia's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
What does a Return-on-Tangible-Asset of 0.73% mean?
Farmaceutica Remedia (LTS:0M8I) has a Return-on-Tangible-Asset of 0.73% as of Mar. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Farmaceutica Remedia and its competitors. This is 66% below median its historical median of 2.13. Over the past decade, Farmaceutica Remedia's Return-on-Tangible-Asset has ranged from 0.87 to 15.13. According to the industry distribution chart, Farmaceutica Remedia ranks #74 out of 120 companies in the Medical Distribution industry, placing it in the top 61.7%.
Is Farmaceutica Remedia's Return-on-Tangible-Asset too high?
Farmaceutica Remedia's current Return-on-Tangible-Asset of 0.73% is 66% below median its 10-year median of 2.13. Over the past 10 years, this metric has ranged from a low of 0.87 to a high of 15.13. The Medical Distribution industry median Return-on-Tangible-Asset is 2.43. Farmaceutica Remedia's value of 0.73% is 70% below this industry median. Based on the distribution chart, Farmaceutica Remedia ranks #74 out of 120 companies in the Medical Distribution industry, which is below the industry midpoint. Overall, Farmaceutica Remedia has a GF Score™ of 58/100, reflecting its overall financial health beyond just this single metric.
How does Farmaceutica Remedia's Return-on-Tangible-Asset compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Farmaceutica Remedia ranks #74 out of 120 companies for Return-on-Tangible-Asset. This places Farmaceutica Remedia in the lower half of its industry. The industry median Return-on-Tangible-Asset is 2.43. Farmaceutica Remedia's value of 0.73% is 70% below this benchmark. Historically, Farmaceutica Remedia's own Return-on-Tangible-Asset has ranged from 0.87 to 15.13 over the past decade. While the company's 10-year median is 2.13 vs. the industry median of 2.43, Farmaceutica Remedia has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Medical Distribution company?
The median Return-on-Tangible-Asset among Medical Distribution companies is 2.43, based on 120 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Farmaceutica Remedia's current Return-on-Tangible-Asset of 0.73% is 70% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Farmaceutica Remedia and its competitors. For the Medical Distribution industry, the median Return-on-Tangible-Asset is 2.43 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Farmaceutica Remedia's current Return-on-Tangible-Asset is 0.73%, which is 66% below median its own 10-year median of 2.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Farmaceutica Remedia stock overvalued right now?
Farmaceutica Remedia (LTS:0M8I) has a current Return-on-Tangible-Asset of 0.73%. The stock's GF Value™ is lei0.23, compared to a current price of lei0.25 — trading 8.7% above its estimated fair value. The current Return-on-Tangible-Asset is 0.73%, which is 66% below median its 10-year median of 2.13 and 70% below the Medical Distribution industry median of 2.43. Farmaceutica Remedia's overall GF Score™ is 58/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Farmaceutica Remedia (LTS:0M8I), the current Return-on-Tangible-Asset is 0.73% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Farmaceutica Remedia (LTS:0M8I) Overvalued in 2026?
Based on GuruFocus' analysis, Farmaceutica Remedia stock appears to be overvalued.
The current stock price of lei0.25 is trading 8.7% above its estimated GF Value™ of lei0.23.
Key valuation signals for LTS:0M8I:
Return-on-Tangible-Asset: 0.73% (66% below median its 10-year median of 2.13)
GF Value™: lei0.23 vs. price of lei0.25 (8.7% above fair value)
Industry Position: 70% below the Medical Distribution median (#74 of 120)
No single metric tells the full story. See the LTS:0M8I stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Farmaceutica Remedia SA is engaged in drug sales activities, marketing, and health products. It provides marketing and promotion services for medicines. The company offers services offered, including logistics services, medical marketing, and promotion, and pharmaceutical registrations, but also professionalism and performance differentiate the company from other competitors and position it as a partner for launching, promoting, and distributing pharmaceutical products in Romania and other countries in Eastern Europe.
58GF Score
Get the complete analysis for LTS:0M8I
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0M8I has been successfully added to your 
